Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Drinabant - Opiant Pharmaceuticals

Next Previous
Search
Drug Profile

Drinabant - Opiant Pharmaceuticals

Alternative Names: AVE 1625; INDV-5004; OPNT-004

Latest Information Update: 28 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator sanofi-aventis
  • Developer Opiant Pharmaceuticals; sanofi-aventis
  • Class Antidementias; Antihyperglycaemics; Antiparkinsonians; Antipsychotics; Halogenated hydrocarbons; Obesity therapies; Small molecules; Sulfonamides
  • Mechanism of Action Cannabinoid receptor CB1 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Alzheimer's disease; Obesity; Parkinson's disease; Schizophrenia; Substance-related disorders; Type 2 diabetes mellitus

Most Recent Events

  • 28 Dec 2024 No recent reports of development identified for preclinical development in Substance-related disorders in USA (Parenteral, Injection)
  • 25 Jul 2024 Discontinued - Preclinical for Substance-related disorders in USA (Parenteral)
  • 02 Mar 2023 Opiant Pharmaceuticals has been acquired by Indivior

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top